Ecosystem value hotspots

Ecosystem value hotspots

The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. We supported key value-based strategic decisions with an ecosystem perspective.

Diabetic obesity

Diabetic obesity

Our client wished to design an ecosystem strategy for behavioural, drug and clinical health technologies that help at-risk obese persons to lose and maintain weight.

Surgical risk

Surgical risk

Our client - an EU 2.2bn global fiber-based materials company - was suffering from declining market share in its core surgical gowns and drapes market. To recover, it sensed growth potential in a new market segment characterised by particular types of surgical procedures.

Nursing home continence

Nursing home continence

Our client, a top 3 manufacturer of continence supplies, wished to formulate a North American ecosystem strategy for the larger institutional segment of its business.  

Infection prevention

Infection prevention

A top 30 multi-national pharmaceutical wished to undertake an in-depth disease area strategy review to decide whether to reacquire the commercial rights to its currently out-licensed infection prevention and treatment technology. 

Living with a stoma

Living with a stoma

We helped to establish the "listen and respond" approach to product innovation at Coloplast, a global Danish-based wound and skin care medical device company.

Wound infection

Wound infection

A global wound care company asked us to advise on the detailed nature of the ecosystem opportunity for a new diagnostic technology which sought to help healthcare practitioners, patients and consumers identify early indicators of wound  infection at the point-of-care.

Perinatal care

Perinatal care

Our client wished to identify value-creation "hot spots" in European perinatal care ecosystems. With these hotspots identified, they then wished to identify and assess technology, drug and device assets that had the greatest potential to address them. With these identified and profiled, we supported our client to perform deeper dive assessments into target assets based on demand, impact, ecosystem and commercial value.

Diabetic foot infection

Comment

Diabetic foot infection

In 2008, ITI Scotland announced its wish to invest £7.9 Million over three and a half years in the development of advanced point of care wound infection diagnostic technology, specifically targeting diabetic foot ulcer wounds.

Comment